2015 International AIDS Society Conference
July 20, 2015 – 2015 International AIDS Society Conference: New CDC Research on HIV PrEP
This week, at the 2015 International AIDS Society Conference in Vancouver, CDC researchers will present important research findings on HIV prevention. The National Institutes of Health announced findings from the ADAPT trial, a clinical study designed to identify the HIV pre-exposure prophylaxis, or PrEP, pill-taking schedules that people are most likely to follow. The study found that young, South African women, as well as men who have sex with men and transgender women in New York and Thailand, can adhere to a daily PrEP regimen. Adherence to the daily regimen was higher than adherence to the two non-daily regimens at all three study sites. CDC conducted the Bangkok arm of the study in collaboration with the Bangkok Metropolitan Administration and the Thailand Ministry of Public Health.
CDC researchers presented findings showing that heterosexual men and women in Botswana enrolled in the 12-month open-label extension of the TDF2 clinical trial were highly adherent to a daily oral combination of tenofovir and emtricitabine (TDF/FTC) for PrEP. Further, sexual risk behavior declined over the course of the study. Finally, a sub-analysis by gender confirms that women who are at risk for HIV are able to adhere to daily PrEP. This is encouraging since some PrEP studies have found that women were not protected from HIV because they did not take the medication regularly, as prescribed.
For your stories about this new research, please find below relevant media materials, as well as other useful background resources.
- Press Release: Young South African Women Can Adhere to Daily PrEP Regimen as HIV Prevention, Study FindsExternal
- Media Summary: New study finds high adherence to daily pill for HIV prevention among both men and women – Sub-analysis underscores the value of PrEP in protecting women’s health
- Background Material